平凌燕, 宋玉琴, 郑文, 林宁晶, 王小沛, 涂梅峰, 应志涛, 刘卫平, 邓丽娟, 张晨, 朱军. 克拉屈滨治疗18例复治惰性B细胞淋巴瘤的临床分析[J]. 中国肿瘤临床, 2011, 38(18): 1120-1123. DOI: 10.3969/j.issn.1000-8179.2011.18.017
引用本文: 平凌燕, 宋玉琴, 郑文, 林宁晶, 王小沛, 涂梅峰, 应志涛, 刘卫平, 邓丽娟, 张晨, 朱军. 克拉屈滨治疗18例复治惰性B细胞淋巴瘤的临床分析[J]. 中国肿瘤临床, 2011, 38(18): 1120-1123. DOI: 10.3969/j.issn.1000-8179.2011.18.017
shu
Lingyan PING, Yuqin SONG, Wen ZHENG, Ningling LIN, Xiaopei WANG, Meifeng TU, Zhitao YING, Weiping LIU, Lijuan DENG, Chen ZHANG, Jun ZHU. Clinical Analysis of Cladribine in 18 Heavily Retreated Patients with Indolent B-cell Lymphoma[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2011, 38(18): 1120-1123. DOI: 10.3969/j.issn.1000-8179.2011.18.017
Citation: Lingyan PING, Yuqin SONG, Wen ZHENG, Ningling LIN, Xiaopei WANG, Meifeng TU, Zhitao YING, Weiping LIU, Lijuan DENG, Chen ZHANG, Jun ZHU. Clinical Analysis of Cladribine in 18 Heavily Retreated Patients with Indolent B-cell Lymphoma[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2011, 38(18): 1120-1123. DOI: 10.3969/j.issn.1000-8179.2011.18.017
shu

克拉屈滨治疗18例复治惰性B细胞淋巴瘤的临床分析

Clinical Analysis of Cladribine in 18 Heavily Retreated Patients with Indolent B-cell Lymphoma

    摘要
  • 摘要: 探讨克拉屈滨用于复治惰性B细胞淋巴瘤的有效率及安全性。方法：回顾性分析2009年12月至2011年4月本院淋巴肿瘤科使用克拉屈滨治疗的18例惰性B细胞淋巴瘤患者的疗效及安全性。结果：18例患者中中位发病年龄54.5岁，临床分期为Ⅲ～Ⅳ期占88.3%，10例患者使用过2种或2种以上化疗方案，使用克拉屈滨之前的平均化疗周期数11.6个，中位数为8个周期（2～57个）。13例患者完成2个周期或以上克拉屈滨联合环磷酰胺（CC）方案化疗，5例患者仅使用1个周期化疗，总有效率27.8%，完全缓解率（CR）16.7%。骨髓抑制为主要不良反应，3～4级粒细胞减少症发生率为33.3%。结论：克拉屈滨对复发惰性B细胞淋巴瘤显示出一定的有效率，安全性良好。

     

    Abstract: To analyze the response rate and security of cladribine in heavily retreated patients with indolent B-cell lymphomas. Methods: Clinical records of 18 cases of indolent B-cell lymphomas treated with a cladribine combined with cyclophosphamide ( CC ) regimen were retrospectively analyzed. Results: Among the 18 patients, 9 were diagnosed as grade 1-2 follicular lymphoma. The median age was 54.5 years, with marked male predominance ( 1.25:1 ). Up to 88.7% of patients were of clinical stages Ⅲ to Ⅳ, 16.7% of patients had B symptoms, 38.9% of patients were with elevated lactate dehydrogenase. Up to 13 patients completed 2 or more cycles of the CC regimen, 5 patients completed only 1 cycle. The response rate was 27.8%, with a complete remission ( CR ) rate of 16.7%. Myelosuppression was the major toxicity with 33.3% of grades 3 and 4 neutropenia. Conclusion: Cladribine used in the heavily retreated patients of indolent B-cell lymphoma shows good efficacy and is safety.

     

    • HTML全文
    • 参考文献(0)
    • 相关文章
    • 施引文献
  • 资源附件(0)

/

返回文章
返回